Jonny Jonny, Sitepu Enda Cindylosa, Lister I Nyoman Ehrich, Chiuman Linda, Putranto Terawan Agus
Indonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia.
Faculty of Medicine, Dentistry, and Health Sciences, University Prima Indonesia, Medan 20118, Indonesia.
Vaccines (Basel). 2024 Aug 27;12(9):972. doi: 10.3390/vaccines12090972.
A typical consequence of type 2 diabetes mellitus, diabetic kidney disease (DKD) is a significant risk factor for end-stage renal disease. The pathophysiology of diabetic kidney disease (DKD) is mainly associated with the immune system, which involves adhesion molecules and growth factors disruption, excessive expression of inflammatory mediators, decreased levels of anti-inflammatory mediators, and immune cell infiltration in the kidney. Dendritic cells are professional antigen-presenting cells acting as a bridge connecting innate and adaptive immune responses. The anti-inflammatory subset of DCs is also capable of modulating inflammation. Autologous anti-inflammatory dendritic cells can be made by in vitro differentiation of peripheral blood monocytes and utilized as a cell-based therapy. Treatment with anti-inflammatory cytokines, immunosuppressants, and substances derived from pathogens can induce tolerogenic or anti-inflammatory features in ex vivo-generated DCs. It has been established that targeting inflammation can alleviate the progression of DKD. Recent studies have focused on the potential of dendritic cell-based therapies to modulate immune responses favorably. By inducing a tolerogenic phenotype in dendritic cells, it is possible to decrease the inflammatory response and subsequent kidney damage. This article highlights the possibility of using anti-inflammatory DCs as a cell-based therapy for DKD through its role in controlling inflammation.
糖尿病肾病（DKD）是2型糖尿病的典型并发症，是终末期肾病的重要危险因素。糖尿病肾病（DKD）的病理生理学主要与免疫系统相关，涉及黏附分子和生长因子紊乱、炎症介质过度表达、抗炎介质水平降低以及肾脏免疫细胞浸润。树突状细胞是专业的抗原呈递细胞，是连接先天性和适应性免疫反应的桥梁。树突状细胞的抗炎亚群也能够调节炎症。自体抗炎树突状细胞可通过外周血单核细胞的体外分化制备，并用作基于细胞的治疗方法。用抗炎细胞因子、免疫抑制剂和病原体衍生物质进行治疗可在体外生成的树突状细胞中诱导耐受性或抗炎特性。已经证实，针对炎症可以缓解DKD的进展。最近的研究集中在基于树突状细胞的疗法有利地调节免疫反应的潜力上。通过在树突状细胞中诱导耐受性表型，有可能减少炎症反应和随后的肾脏损伤。本文强调了通过抗炎树突状细胞在控制炎症中的作用，将其用作DKD基于细胞的治疗方法的可能性。
